Molecular Discovery Grants
Last MDG Cycle: February 2020
The Michigan State University Molecular Discovery Grants (MSU-MDG) have been established between the Department of Pharmacology & Toxicology and MSU Drug Discovery to provide pilot funding for accelerating the discovery and development of chemical technologies with applications for human health, animal health and agricultural use (max $30,000; average: $10,000- 15,000). The primary aim of these funds is to advance projects toward extramural funding or to the creation or development of intellectual property and commercialization.
Specific goals include:
• Assisting investigators in advancing their programs in the early phases of the discovery process with long-term commercialization in mind.
• Supporting early activities (e.g. screening) not readily funded by other sources.
• Providing additional data to support extramural grant applications.
• Aiding in the discovery or development of intellectual property.
• Accelerating therapeutics or diagnostics discovery and development programs
|4||Jason Bazil, Ph.D.||The search for Novel Mitoprotectants Against Reperfusion Injury|
|Bryan Copple, Ph.D.||Development of Machrphage Phenotypic Modulators as a Treatment for Liver Fibrosis|
|Sean Crosson, Ph.D.||High Throughput Screening for Host-Directed Antimicrobials Against Intracellular Brucella|
|Kathleen Gallo, Ph.D.||Mixed Lineage Kinase 3 Inhibitors for Glioblastoma|
|Jian Hu, Ph.D.||Developing Cell-based High Throughput Screening to Identify Inhibitors Against Pathogenic Fungal ZIP Metal Transporters|
|Kin Sing Stephen Lee, Ph.D.||Developing a sHE inhibitor with Improved Physicochemical Properties and CNS Penetration for Lupus|
|Jeffrey MacKeigan, Ph.D||Small Molecule Inhibitors of ULK1|
|Aaron Odom, Ph.D. /Jetze Tepe, Ph.D.||Exploration of in vivo Efficacy of Proteasome Inhibitors with Alternative Mechanisms|
|Bryan Smith, Ph.D.||Marophage-selective Nanotherapy to Treat Breast Cancer|
|3||Robert Abramovitch, Ph.D.||Development of New Mycobacterium tuberculosis MmpL3 Inhibitors|
|Bryan Copple, Ph.D.||Modulation of Macrophage Phenotype to Treat Liver Fibrosis and Cirrhosis|
|Andrea Doseff, Ph.D. / Karen Liby, Ph.D.||Identifying Novel Strategies for the Treatment of Triple Negative Breast Cancer|
|Erika Lisabeth, Ph.D.||Identification of Small Molecule Modulators of the Serum Response Factor|
|Dohun Pyeon, Ph.D.||Developing Chemokine-based Novel Immunotherapies|
|Christopher Waters, Ph.D.||Identifying Triclosan Analogs That Improve Synergy with Tobramycin to Eradicate Biofilms|
|2||Susan Conrad, Ph.D.||Identifying Novel Strategies for Endocrine-resistant Metastatic ER+ Breast Cancer|
|Aaron Odom, Ph.D. / Jetze Tepe, Ph.D.||Exploration of Viability of Proteasome Inhibitors with Alternative Mechanisms|
|Chrisopher Waters, Ph.D.||Identifying Compounds That Enhance Biocide Killing of Waters System Biofilms|
|Stephanie Watts, Ph.D.||5-HT7 Receptor Drug Discovery for Cardiovascular Disease|
|Yong-Hui Zheng, Ph.D.||High Throughput Screening of Novel Anti-HIV-1 Compounds|
|1||Robert Abramovitch Ph.D.||Medicinal Chemistry Optimizations of Lead Compounds That Inhibit M. tuberculosis Persistence and drug tolerance|
|Andre Bachmann Ph.D.||Synthesis of Biological Evaluation of Phaseolotoxin-inspired ODC Inhibitors|
|Jon Kaguni Ph.D.||Targeted Drug Discovery to Identify Inhibitors of Bacterial DNA Replication|
|Hao-Min Kuo Ph.D.||Hyperphosphorylated tau Aggregation modulators as Candidates for Alzheimer's disease Therapeutics and Risk Factors|
|Karen Liby, Ph.D.||Synthesis and Characterization of New Rexinoids|
|Jetze Tepe, Ph.D.||Development of Drug-like TCH-165 Derivatives|